Last reviewed · How we verify
group M
This drug works by inhibiting the activity of the M protein.
This drug works by inhibiting the activity of the M protein. Used for Treatment of influenza A and B.
At a glance
| Generic name | group M |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Antiviral |
| Target | M protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | FDA-approved |
Mechanism of action
The M protein is a key component of the influenza virus, and by inhibiting its activity, the drug prevents the virus from replicating. This leads to a reduction in the severity and duration of influenza symptoms.
Approved indications
- Treatment of influenza A and B
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Effects of Training With a Pressure Cuff on Cellular Energy Activity (NA)
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- Exercise for the Treatment of Cancer-Related Sarcopenia (NA)
- Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment (PHASE1, PHASE2)
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer (PHASE1, PHASE2)
- Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer (PHASE1, PHASE2)
- Cognitive Processing Therapy for Childbirth-Related Post-Traumatic Stress Disorder (NA)
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- group M CI brief — competitive landscape report
- group M updates RSS · CI watch RSS
- Ain Shams University portfolio CI